Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
150 Leser
Artikel bewerten:
(0)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Idenix Pharmaceuticals, Inc. in Connection With The Sale of The Company - IDIX

BALA CYNWYD, Pa., June 13, 2014 /PRNewswire/ --Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Idenix Pharmaceuticals, Inc. ("Idenix" or the "Company") (Nasdaq: IDIX) relating to the proposed acquisition by Merck & Co., Inc. ("Merck").

Click here to learn more about the investigation http://brodsky-smith.com/766-idix-idenix-pharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Idenix shareholders will receive only $24.50 in cash for each share of Idenix stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Idenix for not acting in the Company's shareholders' best interests in connection with the sale process.

Further, the investigation seeks to determine if the transaction undervalues Idenix given that is has been reported that Merck may need Idenix's drug Samatasvir and two of the Company's clinical-stage drugs to combine with its own oral hepatitis C compounds. In addition, Idenix claims that Gilead is infringing on one of its key patents which, if successful, could lead to a large upfront payment or even a steady royalty payment.

If you own shares of Idenix common stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com, by visiting http://brodsky-smith.com/766-idix-idenix-pharmaceuticals-inc.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE Law Office of Brodsky & Smith, LLC

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.